Clinical Trials
119
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (91 trials with phase data)• Click on a phase to view related trials
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
- Conditions
- HypertensionAcute Heart FailureDyspnea
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- The Medicines Company
- Registration Number
- NCT04592380
- Locations
- 🇺🇸
Drug Research and Analysis Corporation/Jackson Hospital, Montgomery, Alabama, United States
🇺🇸University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
- Conditions
- ASCVDRisk Factor, CardiovascularElevated Cholesterol
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 1617
- Registration Number
- NCT03400800
- Locations
- 🇨🇿
Research Site 11420-002, Chomutov, Czechia
🇨🇿Research Site 11420-003, Uherské Hradiště, Czechia
🇩🇪Research Site 11049-006, Berlin, Germany
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
- Conditions
- ASCVDElevated Cholesterol
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 1561
- Registration Number
- NCT03399370
- Locations
- 🇺🇸
Research Site 10001-015, Birmingham, Alabama, United States
🇺🇸Research Site 10001-138, Foley, Alabama, United States
🇺🇸Research Site 10001-113, Huntsville, Alabama, United States
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
- Conditions
- Elevated CholesterolHeterozygous Familial Hypercholesterolemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 482
- Registration Number
- NCT03397121
- Locations
- 🇺🇸
Site 90001-005, Mission Viejo, California, United States
🇺🇸Site 90001-001, Newport Beach, California, United States
🇺🇸Site 90001-015, Stanford, California, United States
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 31
- Registration Number
- NCT03159416
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next